Teva Pharmaceutical Industries Ltd is more commonly known simply as Teva Pharmaceuticals. TEVA are an American-Israeli pharmaceutical company. They have dual headquarters in:
New Jersey, U.S
Field of Expertise
This pharma company specialise primarily in generic drugs. However they do still have a number of other business interests. Including active pharmaceutical ingredients and, to a lesser degree, proprietary pharmaceuticals.
Teva Pharmaceuticals are the largest generic drug manufacturer in the world. They are also one of the 15 largest pharmaceutical companies worldwide. Their facilities are located in Israel, North America, Europe, Australia, and South America. Teva shares are listed on the Tel Aviv Stock Exchange. The company is a member of the Pharmaceutical Research and Manufacturers of America.
Teva are actually a leading provider of medicines to the NHS here in the UK. This Enables millions of patients here in the UK the ability to live a better life. Whilst even helping the NHS to actually save money.
Their generic medicines help take pressure off of the NHS by saving them around £3 billion a year.
What Teva say
“Our commitment to patients and their health is steadfast. We recognise this tremendous responsibility and also see it as an opportunity to improve lives and to make a lasting social impact.”
“Shaped by patients, for patients – support for those living with chronic conditions.”
Contributing to healthy communities
(Teva in their own words)
For Teva, a healthy community is one in which all individuals have access to resources. And those who have conditions that enable them to live their healthiest lives. Cultivating healthier communities allows us to support people around the world on their individual paths toward wellness, thereby creating value for society and our business.
At Teva, we help communities get, and stay healthy. By providing affordable medicines, collaborating with patient groups and other organisations, starting health initiatives and engaging in innovative research.
They’re proud of what they’ve achieved already. Their efforts have had a positive impact on the lives of people and the health of communities.
The efforts made already to contribute to healthier communities serve as proof points. That as a brand, Teva is committed to making a positive social impact. We do this by aligning resources with the expertise and experience of our people to support relevant areas of social need. And we are fully committed to operating as an ethical, enduring business, with the understanding that this is critical to continue bringing value to our organisation and to society.
We deliver health to patients through our:
> Teva Pharmaceuticals are the world’s leading provider of generic medicines. Our expertise in specialty treatments is focused on disorders of the central nervous system, respiratory disease, cancer, and pain. We also supply the pharmaceutical industry with high-quality active pharmaceutical ingredients (APIs), ingredients in a pharmaceutical drug that are pharmacologically active.
Launched approximately 1,000 generics globally
Offered 16,000 products and 50,000 SKUs
Held top 3 position for generics in 25 markets
Supplied 370+ APIs to nearly 1,000 customers in 100 countries
> We engage in programs to support and improve quality of life for patients and their families.
Supported 80+ patient educational programs
Reached 300,000+ patients in 38 countries through supported programs
Covered various therapeutic areas, including multiple sclerosis and cancer
> We reimagine, innovate, and co-create health solutions to improve understanding of medicine and reach high-need patients.
Invested $1.8B+ USD in research and development, a significant portion supporting patients with no alternative therapy
Funded $350,000+ USD in genetic disorder and autism brain mechanism research with Israel’s Bar-Ilan University
In collaboration with FHI 360 and Bill & Melinda Gates Foundation, developing an injectable contraceptive for six-month protection
> We join forces with peers, stakeholders, and organizations across sectors, leveraging diverse skills and resources to mitigate barriers to access, support patients and their families, and advocate for patients across disease areas.
Convened 17 global patient advocacy groups (total membership of 2,000 organizations in 50 disease areas across 170 countries) via Improving Health Global Patient Advocacy Dialogue
Sponsored and participated in the inaugural conference of healthcare experts to address leveraging generics and biosimilars to meet unmet patient needs through the Value Added Medicines group of Medicines for Europe, which Teva chairs
Non-Communicable Diseases (NCDs) and Multiple Chronic Conditions.
One of our big focus areas at the moment is addressing the challenge of Non-communicable diseases (NCDs).
NCDs are not passed from person to person. They are typically of a long duration and progress slowly. The most common NCDs include cardiovascular diseases (such as heart attacks and stroke), cancers, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma), and diabetes.
As life expectancy increases, the number of people who eventually develop NCDs continues to grow. Teva is committed to addressing the burden of NCDs and improving patient lives.
Through ongoing conversations with health leaders and patients, we identified an emerging global health challenge directly related to NCDs; that of Multiple chronic conditions.
Multiple chronic conditions (MCC) are characterised by the presence of two or more chronic conditions. These can include chronic diseases—most of which are non-communicable, such as cardiovascular diseases, but also some communicable diseases, such as tuberculosis and human immunodeficiency virus.
MCC magnifies the complexity of treatment, exponentially increases healthcare costs and, most importantly, affects individuals, caregivers, communities, and health systems.
Through multisectoral partnerships, Teva is committed to helping address MCC by supporting design and implementation of evidence-based care programs targeting concrete outcomes. Working together, we have the potential to improve the quality of life for people with MCC and their caregivers while also decreasing health costs to individuals and society.
Partnering to address antimicrobial resistance with industry leaders
Antimicrobial resistance (AMR) occurs when bacteria and related illnesses become resistant to antibiotics. Without effective antibiotics, infectious diseases can become deadly outbreaks, not just in humans, but also in our global food supply.
Addressing antibiotic effectiveness and understanding how alternative approaches can treat and prevent infections is a top priority. Teva is committed to being a part of the solution.